[REVISION HISTORY]

CSL Ltd share price volatility and recovery efforts

Updated 7 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-02 03:22 UTC → 2026-09-09 19:43 UTC · added ~~removed~~

CSL Ltd’s shares experienced significant volatility throughout mid-2026. After hitting a nine-year low in early June, the stock saw a sharp rebound of approximately 35%, rising from $91 to $122.89. This recovery was largely attributed to sector rotation and valuation re-assessments rather than company-specific news, as investors weighed the firm’s stable dividend yield—roughly 3.15%—against operational headwinds. Despite the rally, sentiment remains cautious. Analysts have largely shifted to a ‘hold’ stance, citing concerns over US immunoglobulin supply constraints, China albumin pricing pressure, and the US$5 billion non-cash impairment from the Vifor acquisition. Additionally, uncertainty persists regarding the Tavneos product, which faces potential regulatory hurdles in the EU. On 29 July, the company announced a next-generation plasma manufacturing plan using its patented Horizon 2 technology to boost immunoglobulin yields, triggering a 6% share price jump. ~~By mid-August, shares rallied another 12% as investors anticipated FY26 financial results.~~ Following the release of FY26 results, ~~the company~~ which reported revenue of US$15.8 billion and an underlying NPATA of US$3.1 ~~billion. While the company reported~~ billion against a statutory loss of $2.6 ~~billion—impacted~~ billion, the stock continued its upward trajectory. By early September, shares had surged approximately 90% from the low of $90 reached in June, despite a minor dip to $171.21. Investors have largely looked past the statutory loss, noting it was driven by US$7.1 billion in non-cash pre-tax impairments and US$799 million in restructuring ~~costs—it has announced an A$1.1 billion buyback for FY27 and guides toward~~ costs. For FY27, CSL expects underlying ~~profit~~ NPAT growth of approximately ~~5% at constant currency. Management characterized~~ 5%, exceeding consensus estimates of 2%. While the ~~period as a ‘reset year’ with expectations for~~ Vifor division faces a ~~return~~ projected 25% revenue decline due to ~~growth~~ competition in ~~FY27. Leadership and structural changes are also underway. The company is conducting a “well-advanced” global search for a permanent CEO to succeed interim CEO Gordon Naylor, and is managing~~ the ~~potential demerger of its Seqirus influenza vaccine business by the end of FY26. By late August, CSL shares completed a substantial recovery, rising approximately 86% to 88%~~ iron generics market, growth is expected from the ~~multi-year low of $92.24 reached in June to a price of approximately $173.38.~~ Behring and Seqirus divisions.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.